Hologic hails improved outlook following strong fourth quarter

Hologic has announced its financial results for the fourth and final quarter of 2014, during which it delivered a reported revenue total of $660.6 million (415.99 million pounds).

This represented a year-on-year increase of 6.2 percent and included a one-time revenue benefit of $20.1 million related to an amended license agreement with Roka Bioscience. Improved results were generated by all four of Hologic's business segments.

Although the 2014 business year began with declining performance trends, the firm has been able to turn this around and establish a clear path to sustainable organic growth. The diagnostics business generated the greatest proportion of its revenues, though the skeletal health division saw the most rapid growth.

Operational revenue growth, excluding the impact of foreign currency, is expected to be between two percent and 3.5 percent in the 2015 fiscal year.

Stephen MacMillan, president and chief executive officer of Hologic, said: "While we still have work to do, we have put the pieces in place to drive accelerating growth and are much better positioned as we head into fiscal 2015."

Last month, the firm announced that its 2,000th 3D mammography system has now been installed worldwide, highlighting the considerable success of the technology since its launch.